These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20446588)

  • 21. Impact of metabolic syndrome, diabetes and prediabetes on cardiovascular events: Tehran lipid and glucose study.
    Hadaegh F; Shafiee G; Ghasemi A; Sarbakhsh P; Azizi F
    Diabetes Res Clin Pract; 2010 Mar; 87(3):342-7. PubMed ID: 20004035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The PROactive Study: pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes.
    Pratley RE
    Curr Diab Rep; 2006 Feb; 6(1):45-6. PubMed ID: 16522280
    [No Abstract]   [Full Text] [Related]  

  • 23. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
    Lehmann DF; Lohray BB
    J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
    [No Abstract]   [Full Text] [Related]  

  • 24. Introduction: Symposium on diabetes, inflammation and cardiovascular disease.
    Smith U
    J Intern Med; 2007 Aug; 262(2):142-4. PubMed ID: 17645582
    [No Abstract]   [Full Text] [Related]  

  • 25. Preservation of β-cell function: the key to diabetes prevention.
    DeFronzo RA; Abdul-Ghani MA
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2354-66. PubMed ID: 21697254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Inquiries: How can we keep impaired glucose tolerance and impaired fasting glucose from progressing to diabetes?
    Swanson A; Watrin K; Wilder L
    J Fam Pract; 2010 Sep; 59(9):532-3. PubMed ID: 20824232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular prevention in patients with diabetes and prediabetes.
    Anselmino M; Gohlke H; Mellbin L; Rydén L
    Herz; 2008 Apr; 33(3):170-7. PubMed ID: 18568310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological strategies for preventing type 2 diabetes in patients with impaired glucose tolerance.
    Smith-Marsh D
    Drugs Today (Barc); 2013 Aug; 49(8):499-507. PubMed ID: 23977667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
    Home P
    Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.
    Tuomilehto J; Lindström J; Hellmich M; Lehmacher W; Westermeier T; Evers T; Brückner A; Peltonen M; Qiao Q; Chiasson JL
    Diabetes Res Clin Pract; 2010 Feb; 87(2):267-74. PubMed ID: 20022651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delaying the onset of type 2 diabetes mellitus in patients with prediabetes.
    Irons BK; Mazzolini TA; Greene RS
    Pharmacotherapy; 2004 Mar; 24(3):362-71. PubMed ID: 15040650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular effects of the thiazolidinediones.
    Qayyum R; Schulman P
    Diabetes Metab Res Rev; 2006; 22(2):88-97. PubMed ID: 16184618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
    Shin JJ; Rothman J; Farag A; McFarlane SI; Sowers JR
    Minerva Med; 2003 Dec; 94(6):401-8. PubMed ID: 14976468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New subgroup analysis of the PROactive Study. Risk for recurrent stroke cut in half].
    MMW Fortschr Med; 2006 Oct; 148(41):50-1. PubMed ID: 17190265
    [No Abstract]   [Full Text] [Related]  

  • 35. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G
    J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Infarct prevention for diabetics. To lower blood sugar is not enough].
    MMW Fortschr Med; 2001 Nov; 143(46):61. PubMed ID: 11759608
    [No Abstract]   [Full Text] [Related]  

  • 38. Prevention of type 2 diabetes in the prediabetic population.
    Maji D; Roy RU; Das S
    J Indian Med Assoc; 2005 Nov; 103(11):609-11. PubMed ID: 16570766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].
    MMW Fortschr Med; 2003 Sep; 145(38):61. PubMed ID: 14603688
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.
    Ratner RE; Cannon CP; Gerstein HC; Nesto RW; Serruys PW; Van Es GA; Kolatkar NS; Kravitz BG; Zalewski A; Fitzgerald PJ;
    Am Heart J; 2008 Dec; 156(6):1074-9. PubMed ID: 19033001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.